Central Nervous System Pharmacology Practice Questions

Q: Which drug class is commonly used as a first-line treatment for neuropathic pain?

Antiepileptics. ***Antiepileptics*** - Certain antiepileptics, particularly **gabapentin** and **pregabalin**, are considered **first-line agents** for neuropathic pain due to their ability to modulate **neurotransmitter release** in the central nervous system. - They work by binding to the **α2δ subunit of voltage-gated calcium channels**, reducing neuronal excitability. - These are often **preferred first-line** due to better tolerability compared to other first-line options. *Tricyclic antidepressants (TCAs)* - TCAs like **amitriptyline** and **nortriptyline** are also considered **first-line agents** for neuropathic pain by major guidelines. - However, they are often **less preferred** as initial therapy due to their significant **side effect profile**, such as **anticholinergic effects** and **cardiac toxicity**, especially in elderly patients. - Their mechanism involves **blocking the reuptake of norepinephrine and serotonin**, which modulates descending pain pathways. *Opioids (narcotics)* - **Opioids** are generally reserved for **severe neuropathic pain** that is refractory to first-line agents, due to concerns about **addiction**, **tolerance**, and a broad range of **side effects**. - They exert their analgesic effects by binding to **opioid receptors** in the central and peripheral nervous systems. *Corticosteroids (anti-inflammatory drugs)* - **Corticosteroids** are primarily used for **inflammatory pain** conditions and are generally **ineffective** for the direct treatment of neuropathic pain, which arises from nerve damage or dysfunction. - Their mechanism involves widespread **anti-inflammatory** and **immunosuppressive** effects.

Q: Which drug class is known for treating Parkinson's disease by inhibiting monoamine oxidase type B (MAO-B)?

MAO-B inhibitors. ***MAO-B inhibitors*** - This drug class, which includes **selegiline** and **rasagiline**, specifically targets and inhibits **monoamine oxidase type B (MAO-B)**. - By inhibiting MAO-B, these drugs reduce the breakdown of **dopamine** in the brain, thereby increasing its availability and alleviating Parkinson's symptoms. *Dopamine agonists* - These drugs, such as **pramipexole** and **ropinirole**, directly stimulate **dopamine receptors** in the brain. - While effective in treating Parkinson's, their mechanism of action is **receptor activation**, not enzyme inhibition. *COMT inhibitors* - These drugs, like **entacapone** and **tolcapone**, inhibit **catechol-O-methyltransferase (COMT)**, an enzyme that metabolizes dopamine. - They are used as adjunct therapy to **levodopa** to prolong its effects, but they do not inhibit MAO-B. *Anticholinergics* - This class of drugs, including **benztropine** and **trihexyphenidyl**, targets the **cholinergic system** by blocking acetylcholine receptors. - They are primarily used to manage **tremor** and **dystonia** in Parkinson's disease, but their action is not on dopamine metabolism via MAO-B.

Q: What is the drug of choice for the prophylactic treatment of migraine headaches?

Topiramate. ***Topiramate*** - **Topiramate** is a commonly prescribed and highly effective **antiepileptic drug** that is also approved for the prophylactic treatment of **migraine headaches**. - Its mechanism of action in migraine prevention involves **modulating neurotransmitter activity**, stabilizing neuronal excitability, and potentially reducing cortical spreading depression. *Sumatriptan* - **Sumatriptan** is a **triptan derivative** primarily used for the **acute treatment** of migraine attacks, not for prophylaxis. - It works by **constricting cranial blood vessels** and inhibiting the release of pro-inflammatory neuropeptides to abort an ongoing migraine. *Ibuprofen* - **Ibuprofen** is a **nonsteroidal anti-inflammatory drug (NSAID)** used for the **acute symptomatic relief** of mild to moderate headache pain, including some migraines. - It is not considered a primary drug for the **prophylactic prevention** of chronic migraine headaches. *Paracetamol* - **Paracetamol (acetaminophen)** is an **analgesic and antipyretic** used for general pain relief and fever, and can provide symptomatic relief for mild headaches. - Like ibuprofen, it does not have efficacy as a **prophylactic agent** for migraine prevention, nor is it recommended for this purpose.

Q: A patient presents with severe headaches and is diagnosed with a migraine. Which drug, acting as a serotonin 1D agonist, is used to abort the migraine attack?

Serotonin 1D agonist. ***Serotonin 1D agonist*** - **Triptans**, a class of drugs acting as **5-HT1D/1B receptor agonists**, are the most specific and effective agents for aborting acute migraine attacks. - They work by causing **vasoconstriction of intracranial blood vessels** and inhibiting the release of **pro-inflammatory neuropeptides**. *Dopamine 1 agonist* - **Dopamine agonists** are generally used in conditions like **Parkinson's disease** to improve motor symptoms. - They are not indicated for the acute treatment of migraine as they do not target the specific pathways involved in migraine pathophysiology. *GABAB antagonist* - **GABA-B antagonists** are not used to abort migraine attacks; in fact, **GABA-B agonists** can sometimes be used to manage certain neurological conditions. - These drugs mainly modulate neuronal excitability and have no direct role in the acute vasoconstriction or pain pathways of migraine. *Non-selective beta antagonist* - **Non-selective beta-blockers** (e.g., propranolol) are primarily used for **migraine prophylaxis** (prevention), not for aborting an acute attack. - They work by reducing neuronal excitability and preventing the cascade of events that lead to a migraine, but they do not provide rapid relief during an attack.

Q: A 60-year-old man with Alzheimer's disease has been started on donepezil. What is the primary mechanism of action of this medication?

Acetylcholinesterase inhibitor. ***Acetylcholinesterase inhibitor*** - Donepezil **blocks the enzyme acetylcholinesterase**, which is responsible for breaking down acetylcholine [1], [2]. - By inhibiting this enzyme, donepezil **increases the levels of acetylcholine** in the brain, improving **cholinergic neurotransmission** in patients with Alzheimer's disease [2]. *NMDA receptor antagonist* - **NMDA receptor antagonists** like **memantine** work by blocking the activity of glutamate at the NMDA receptor, which is thought to reduce excitotoxicity in Alzheimer's [1], [3]. - This mechanism is different from donepezil, which targets the **cholinergic system** [1]. *Dopamine receptor antagonist* - **Dopamine receptor antagonists** are primarily used in conditions like **schizophrenia** or **Parkinson's disease** (for psychotic symptoms), by blocking dopamine receptors. - This is not the mechanism of action for medications used to treat cognitive symptoms of Alzheimer's disease. *Serotonin reuptake inhibitor* - **Serotonin reuptake inhibitors (SSRIs)** are a class of antidepressants that increase serotonin levels in the brain by blocking its reuptake [3]. - While depression can co-occur with Alzheimer's, SSRIs do not directly address the cognitive decline associated with the disease [3].

Q: Which of the following non-depolarizing neuromuscular blockers does not cause the release of histamine?

Vecuronium. ***Vecuronium*** - **Vecuronium** is an aminosteroid non-depolarizing neuromuscular blocker known for its minimal cardiovascular effects and **lack of histamine release**. - Its chemical structure (lacking quaternary ammonium groups in certain positions) contributes to its **low propensity for histamine release**, making it suitable for patients with reactive airway disease or cardiovascular instability. *d-tubocurarine* - **d-tubocurarine** is a classic non-depolarizing neuromuscular blocker that is well-known for causing significant **histamine release**, leading to **hypotension** and **bronchospasm**. - Due to its side effect profile, it is rarely used in modern clinical practice. *Atracurium* - **Atracurium** is a benzylisoquinolinium non-depolarizing neuromuscular blocker that can cause **histamine release**, particularly with rapid administration or higher doses. - While its histamine-releasing properties are less pronounced than d-tubocurarine, they can still lead to **cutaneous flushing** and **hypotension**. *Mivacurium* - **Mivacurium** is another benzylisoquinolinium non-depolarizing neuromuscular blocker that is known to cause **histamine release**, especially at higher doses or rapid injection rates. - The histamine release from mivacurium is generally dose-dependent and can result in **flushing** and **transient hypotension**.

Q: What is the drug of choice for juvenile myoclonic epilepsy?

Valproic acid. ***Valproic acid*** - **Valproic acid** is considered the first-line and most effective treatment for **juvenile myoclonic epilepsy (JME)**, effectively controlling myoclonic, generalized tonic-clonic, and absence seizures common in this syndrome. [1] - It works by increasing **GABA activity**, blocking voltage-gated sodium channels, and inhibiting T-type calcium channels, all of which contribute to its broad-spectrum anticonvulsant effects. *Oxcarbazepine* - **Oxcarbazepine** is a sodium channel blocker primarily used for **focal (partial) seizures** and is generally not effective for generalized epilepsies like JME. - It can sometimes worsen myoclonic seizures or generalized tonic-clonic seizures in patients with JME. *Zonisamide* - **Zonisamide** is a broad-spectrum antiepileptic drug that can be used for various seizure types, including generalized seizures, but it is typically a **second-line agent** or an add-on therapy for JME, not the first-line drug of choice. - Its mechanism involves blocking sodium and T-type calcium channels, but its efficacy in JME is generally considered less robust than valproic acid. *Lacosamide* - **Lacosamide** selectively enhances slow inactivation of voltage-gated sodium channels and is approved primarily for the treatment of **focal-onset seizures**. [2] - It is **not recommended** for juvenile myoclonic epilepsy because it can exacerbate myoclonic seizures and generalized tonic-clonic seizures and has no proven efficacy in this epilepsy syndrome.

Q: Which of the following antiepileptic drugs is preferred for treating generalized tonic-clonic seizures?

Valproic acid. ***Valproic acid*** - **Valproic acid** is a broad-spectrum antiepileptic drug effective against various seizure types, including **generalized tonic-clonic seizures**. - It is considered the **gold standard** for generalized seizures because it is effective against all types (absence, myoclonic, and tonic-clonic). - It works by increasing GABA levels, blocking voltage-gated sodium channels, and inhibiting T-type calcium channels. *Ethosuximide* - **Ethosuximide** is specifically used for **absence seizures** (petit mal) and is not effective for generalized tonic-clonic seizures. - It primarily acts by blocking **T-type calcium channels** in the thalamus. *Gabapentin* - **Gabapentin** is primarily used for **focal (partial) seizures** and neuropathic pain, not generalized tonic-clonic seizures. - Its mechanism involves modulating the release of neurotransmitters, possibly by binding to the **α2δ subunit of calcium channels**. *Carbamazepine* - **Carbamazepine** is a first-line treatment for **focal (partial) seizures** and is also effective for **generalized tonic-clonic seizures**, though valproic acid is generally preferred for purely generalized seizures. - It works by blocking voltage-gated sodium channels. - It should be **avoided in absence and myoclonic seizures** as it can worsen these seizure types. - Also used for **trigeminal neuralgia**.

Q: A patient on donepezil for Alzheimer's disease begins to experience bradycardia. What is the likely mechanism of this side effect?

Inhibition of acetylcholinesterase. ***Inhibition of acetylcholinesterase*** - Donepezil is an **acetylcholinesterase inhibitor**, meaning it increases the amount of **acetylcholine** in the synaptic cleft. - Increased acetylcholine activity at muscarinic receptors in the heart, particularly **M2 receptors**, leads to **bradycardia** by decreasing the heart rate and conduction velocity. *Increased GABAergic transmission* - **GABA** (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the central nervous system and primarily affects neuronal excitability, not directly cardiac rhythm. - Medications that increase GABAergic transmission typically cause **sedation** or **anxiolysis**, and are not directly associated with bradycardia as a primary mechanism. *Blockade of NMDA receptors* - **NMDA receptor blockers** (e.g., memantine) are used in Alzheimer's disease to modulate glutamate activity, but they do not directly influence the cholinergic system or heart rate in a way that causes bradycardia. - Their primary effects are on neuronal excitability and neuroprotection, rather than autonomic cardiac function. *Increased dopamine release* - **Dopamine** acts on alpha, beta, and dopaminergic receptors; its release generally tends to **increase heart rate** and cardiac contractility rather than cause bradycardia. - Increased dopamine is not a mechanism of action for donepezil, which specifically targets acetylcholine.

Question 1

Which drug class is commonly used as a first-line treatment for neuropathic pain?

Accepted Answer

Antiepileptics

Answer

Tricyclic antidepressants (TCAs)

Answer

Opioids (narcotics)

Answer

Corticosteroids (anti-inflammatory drugs)

Question 2

Which drug class is known for treating Parkinson's disease by inhibiting monoamine oxidase type B (MAO-B)?

Accepted Answer

MAO-B inhibitors

Answer

Dopamine agonists

Answer

COMT inhibitors

Answer

Anticholinergics

Question 3

What is the drug of choice for the prophylactic treatment of migraine headaches?

Accepted Answer

Topiramate

Answer

Sumatriptan

Answer

Ibuprofen

Answer

Paracetamol

Question 4

A patient presents with severe headaches and is diagnosed with a migraine. Which drug, acting as a serotonin 1D agonist, is used to abort the migraine attack?

Accepted Answer

Serotonin 1D agonist

Answer

Dopamine 1 agonist

Answer

GABAB antagonist

Answer

Non-selective beta antagonist

Question 5

A 60-year-old man with Alzheimer's disease has been started on donepezil. What is the primary mechanism of action of this medication?

Accepted Answer

Acetylcholinesterase inhibitor

Answer

NMDA receptor antagonist

Answer

Dopamine receptor antagonist

Answer

Serotonin reuptake inhibitor

Question 6

Which of the following non-depolarizing neuromuscular blockers does not cause the release of histamine?

Accepted Answer

Vecuronium

Answer

d-tubocurarine

Answer

Mivacurium

Answer

Atracurium

Question 7

What are the roles of cholinesterase inhibitors and NMDA receptor antagonists in the treatment of Alzheimer's disease?

Accepted Answer

Cholinesterase inhibitors enhance cognitive function; NMDA antagonists reduce excitotoxicity

Answer

Cholinesterase inhibitors reduce excitotoxicity; NMDA antagonists enhance cognitive function

Answer

Both target glutamate neurotransmission

Answer

Both improve memory by increasing acetylcholine

Question 8

What is the drug of choice for juvenile myoclonic epilepsy?

Accepted Answer

Valproic acid

Answer

Oxcarbazepine

Answer

Zonisamide

Answer

Lacosamide

Question 9

Which of the following antiepileptic drugs is preferred for treating generalized tonic-clonic seizures?

Accepted Answer

Valproic acid

Answer

Ethosuximide

Answer

Gabapentin

Answer

Carbamazepine

Question 10

A patient on donepezil for Alzheimer's disease begins to experience bradycardia. What is the likely mechanism of this side effect?

Accepted Answer

Inhibition of acetylcholinesterase

Answer

Increased GABAergic transmission

Answer

Blockade of NMDA receptors

Answer

Increased dopamine release

Central Nervous System Pharmacology — MCQs

Central Nervous System Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?